tbuckley/cabot-search huggingface dataset:
Present status of dermabrasion
Authors: E. Epstein
Journal: JAMA (1968)

Probably planing is not here to stay. The cosmetic results do not justify its widespread use by dermatologists as a group in patients with scars of all types and causes. It has some applicability in properly selected individuals treated by experienced operators. The procedure is of definite value in externally caused precancerous skin, especially in actinic keratoses. However, this application is limited by the advanced age of many of these patients, the advent of topical chemosurgery, and the comparatively few physicians experienced in the use of dermabrasion in such conditions. At the present time, cutaneous planing may be regarded as a tottering senior citizen stripped of most of the glorious promise of its meteoric youth.
Hypernatremia in Hospitalized Patients
Authors: Paul M. Palevsky
Journal: Annals of Internal Medicine (1996)

Letters15 November 1996Hypernatremia in Hospitalized PatientsPaul M. Palevsky, MD and Arthur Greenberg, MDPaul M. Palevsky, MDUniversity of Pittsburgh School of Medicine and Veterans Affairs Medical Center, Pittsburgh, PA 15261.University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.Search for more papers by this author and Arthur Greenberg, MDUniversity of Pittsburgh School of Medicine and Veterans Affairs Medical Center, Pittsburgh, PA 15261.University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-10-199611150-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Moritz raises an important issue. We reported an overall hospital mortality rate of 41% in 103 patients who were admitted with hypernatremia or developed the condition during hospitalization. Hypernatremia was judged to be a significant comorbid factor in the deaths of 16% of the patients on the basis of the severity of underlying diagnoses and comorbid conditions and of the temporal relation between hypernatremia and death, even though no deaths were directly attributable to hypernatremia (for example, intracranial bleeding caused by cerebral dehydration). Although delayed or inadequate treatment of hypernatremia was not associated with a statistically significant ... Author, Article, and Disclosure InformationAffiliations: University of Pittsburgh School of Medicine and Veterans Affairs Medical Center, Pittsburgh, PA 15261.University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRegulation of Inflammatory Functions of Macrophages and T Lymphocytes by NFAT5 15 November 1996Volume 125, Issue 10Page: 860KeywordsDeath ratesHemorrhageHospitalizationsHypernatremiaMortality Issue Published: 15 November 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Section Registration
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
This Week in &lt;EMPH&gt;JAMA&lt;/EMPH&gt;
Journal: JAMA (2005)

Lars Wik, MD, PhD; Jo Kramer-Johansen, MD; Helge Myklebust, BEng; Hallstein Sørebø, MD; Leif Svensson, MD; Bob Fellows, MD; Petter Andreas Steen, MD, PhD
FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum salts: A retrospective series of 70 patients.
Authors: C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre, F. Bonnetain, E. Raymond, P. Ruszniewski, C. Louvet, P. Hammel
Journal: Journal of Clinical Oncology (2011)

4132 Background: Gemcitabine-based chemotherapy (CT) is a standard of 1st-line CT in advanced pancreatic adenocarcinoma (PAC) and 5-FU/oxaliplatin combination is an option for second-line (Oettle, J Clin Oncol 2005). Data suggested a potential efficacy of 5-FU/irinotecan CT (FOLFIRI) as 1st-line treatment (Taïeb, Ann Oncol 2007) or in gemcitabine/platinum-refractory advanced PAC (Yoo, Br J Cancer 2009 ; Gebbia, Am J Clin Oncol 2010). We aimed to retrospectively evaluate the efficacy and safety of FOLFIRI regimen as second/third line CT in advanced PAC. Methods: All consecutive patients with advanced PAC (01-2005/05-2010) and OMS≤2, received FOLFIRI-1 (irinotecan 180 mg/m2 D1, n=60) or FOLFIRI-3 CT (irinotecan 100 mg/m2 D1 D3, n=10) after failure of gemcitabine and platinum-based CTs as a systematic policy in our institutions. Data analyzed: tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities. Subgroup analyses were performed to identify prognostic factors. Results: 70 patients were studied. Median age was 60 years (range: 24-81); 52.9% were male; 30 (42.9%) were PS 0, 26 were PS 1 and 14 were PS 2. Cancer was locally advanced in 15.7% and metastatic in 84.3% of patients. Before FOLFIRI regimen, patients received 1 line (n=24, 34.3%), 2 lines (n=40, 57.1%) or ≥ 3 lines (n=6, 8.8%) of CT. TTP with last previous line was 3.8 months. Using FOLFIRI, tumor control was achieved in 31 (44.3%) patients (PR: 5, SD: 26). Median TTP was 3.2 months (CI95%: 2.5-4.2), median OS was 6.7 months (CI95%: 5.4-8.9). Dose adaptation was required in 39 (55.7%) patients. Eighteen (25.7%) patients had grade 3-4 toxicities (haematologic n=13, digestive n=6). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP (0.9 months, HR=6.66, p<0.001) and OS (2.5 months, HR=3.95, p=0.001). Conclusions: FOLFIRI regimen after failure of gemcitabine- and platinum-based CTs for advanced PAC has acceptable toxicity and interesting efficacy limited to patients in good condition (PS 0-1). FOLFIRI regimen should be tested as 1st line CT in patients with advanced PAC.
You Can Be Happily Married
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiogenic shock and disopyramide phosphate
Authors: J. R. Story
Journal: JAMA (1979)

DISOPYRAMIDE phosphate (Norpace) is a recently available antiarrhythmic drug. Although it has electrophysiologic properties similar to those of quinidine, disopyramide has gained popularity because of its fewer gastrointestinal side effects.<sup>1</sup>Toxicity has been reported to be primarily due to anticholinergic effects such as nausea and urinary retention.<sup>1</sup>The drug has also been reported to decrease cardiac output in patients with left ventricular dysfunction,<sup>1-3</sup>and toxic levels of the drug have been implicated as the cause of electrome-chanical dissociation and death in patients with severe heart failure and renal disease.<sup>4</sup>We describe here a patient in whom reversible cardiogenic shock developed after oral administration of disopyramide. <h3>Report of a Case</h3> A 49-year-old man with rheumatic valvular heart disease and suspected associated congestive cardiomyopathy was hospitalized in May 1978 for severe biventricular failure, complicated by a massive pulmonary embolus and frequent premature ventricular beats (PVBs). Discharge medications included
THE FURTHER DEVELOPMENT OF THE SECTIONS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unproven methods of cancer management. Laetrile
Journal: CA A Cancer Journal for Clinicians (1991)

"Laetrile" is used interchangeably with "amygdalin" to designate natural substances, derived primarily from apricots and almonds, that can release cyanide, which is lethal to living organisms. In the 1920s, Dr. Ernst T. Krebs, Sr., formulated a theory that amygdalin could kill cancer cells. His theory was inconsistent with biochemical facts and has since been modified at least twice by his son, Ernst T. Krebs, Jr. Extensive work has been done by cancer scientists to test the claim that Laetrile fights cancer. Many animal experiments in the 1970s showed a complete lack of tumor killing by Laetrile. Reviews of the medical records of patients whose cancers were claimed to be reduced or cured after Laetrile treatment found insufficient medical evidence to judge Laetrile's efficacy. Finally, in a clinical trial in cancer patients reported in 1982, Laetrile neither caused shrinkage of tumors, nor increased survival time, nor alleviated cancer symptoms, nor enhanced well-being. Several reports in the medical literature document instances in which Laetrile has caused serious, life-threatening toxicity when taken in large doses in the manner prescribed by Laetrile advocates. In light of the lack of efficacy of Laetrile and its demonstrated ability to cause harm, Laetrile should not be used to treat cancer.
Environmental Transport and Transformation of Automotive-Emitted Lead
Authors: Warren T. Piver
Journal: Environmental Health Perspectives (1977)

The use of a mass balance equation assists in clarifying the contribution of automotive-emitted lead to the regional and global problems of the distribution of this element, by taking into account the physicochemical transformation processes operating on the lead during its transport along the various environmental pathways. The technical factors which govern the emission of such lead from automobile engines and which affect its subsequent dispersion through the environment are described.
Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
Authors: Toni K. Choueiri, Sumanta Kumar Pal, David F. McDermott, David A. Ramies, Stephanie Morrissey, Yihua Lee, Dale Miles, Jaymes S. Holland, Janice P. Dutcher
Journal: Journal of Clinical Oncology (2012)

364 Background: Cabozantinib (cabo) is an oral, potent inhibitor of MET and VEGFR2 that is currently undergoing clinical efficacy evaluation in several oncology indications. Renal cell carcinoma (RCC) was chosen as an indication in this drug-drug interaction (DDI) study based on involvement of the MET and VEGFR signaling pathways in this disease. The primary objective of this study is to determine the effect of cabo on single dose PK of the CYP2C8 substrate rosiglitazone (rosi). The exploratory objective of this study is to evaluate the preliminary antitumor activity of cabo in pts with RCC. Methods: Eligible pts were required to have RCC with clear cell components with metastases, Karnofsky performance status of ≥70 and measurable disease by RECIST. Pts needed to have experienced PD following standard therapies. Method for DDI study: Day 1, 4 mg rosi; Days 2 - 22, cabo given daily at a dose of 175 mg; Day 22, 4 mg rosi to complete PK assessment for DDI. Cabo continued until PD. On Day 57 and every 8 weeks thereafter subjects underwent tumor assessments by mRECIST. Results: Enrollment is complete at 25 RCC pts with a median of 2 prior regimens; 17/25 (68%) RCC pts had received ≥ 2 lines of prior therapy and 13/25 (52%) with at least 1 VEGF pathway inhibitor and 1 mTOR inhibitor. All pts were intermediate (24/25) or poor (1/25) risk category per Heng et al prognostic strata (JCO 2009). Related AEs ≥ Grade 3 severity: hypophosphatemia 8 (32%), PE 3 (12%; all were incidental / resolved) and diarrhea 3 (12%). Preliminary PK data suggest that clinically relevant doses of cabo do not markedly alter the C max or AUC 0-24h of rosi consistent with lack of inhibition of CYP2C8. RCC pts with confirmed PR by mRECIST: 6/25 (24%). Additionally, 1 pt had an unconfirmed PR. Disease control rate (PR + SD): 68% at 16 weeks; 18/21 (86%) pts with ≥1 post-baseline scan experienced tumor regression (range: 4 – 63% reduction in measurements). 14/25 (56%) remain on cabo with a median follow-up of 4 months. Median PFS and OS have not been reached. Conclusions: Cabo demonstrates encouraging anti-tumor activity in heavily pretreated pts with RCC with a toxicity profile similar to that of other TKIs. Preliminary data suggest no DDI between cabo and rosi (CYP2C8 substrate).
Clinical Cardiology.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of burns with intensive antibiotic therapy and exposure
Authors: G. E. Collentine
Journal: JAMA (1967)

Five hundred patients were treated with intensive parenteral and local administration of antibiotics and with maximum exposure. Analysis of the mortality among this group of patients was performed by the probit method. Comparison of this mortality with that obtained at burn centers that used other methods of treatment suggests that intensive prophylactic antibiotic therapy may have merit in the treatment of severe burns.
A Course of Lectures on Urine, Urinary Deposits, and Calculi
Authors: L. Beale
Journal: BMJ (1860)

sition of the Crystals.IDumb-Bell Crystal. of Oxalate of Lime.Of the Formation of the Dumb-Bell Crystals.Of the Conditions under which the Dumb-Bell Crystal.occur.Deposits often associated with Oxalate of Lime.Of the Examination of Deposits of Oxalate of Lime in the Microscope, aad of their Chemical Characters.Of Oxalate of Lime in a Clinical Point of View.Cystine.Analyses of Urine containing Cystine.Carbonate of Lime.Blood.Corpuscles.Chemical Characters of Urine containing Blood.Of Blood in the Urine clinically.Circular Sporulks closely resembling Blod.Corpucles.BODnES VERY IARELY MET WITH IN UME, AND SUBSTANCES OF A DOUBT.Fur.NATUnE.Cancer-Cell.Tubercle-Corpclks.Sphe- rical Cell.containing Nuclei and Granular Matter.Small Organic Globules.ENTOZOA.Echinococci.Diplosomna Crenata (Farre).Strongylus Gigas.Larva of the Blow- fir.Acari.1V.--Tmn2 CLASs OF UINARtY DEPosrrs.Uric or Lithic Acid.Among the deposits which I have arranged in a third class, and which are characterised by tbeir small bulk, by their crystalline or gi-anular appearance, as well as by their density, may be mentioned, in the first place, uric or lit/tic acid-a substance which has before been brought
Surgical Pathology
Authors: Robert W. Prichard
Journal: JAMA (1989)

Multiauthored texts have long had to endure comments about their inherent unevenness, which seems to vary only in degree. But single-authored texts also vary according to the interests and experience of the author. In the case of this text, however, the unevenness is worthy of comment. Dr Coulson's chapters are among the best. Some of the others badly needed a firm leader and a ruthless editor and did not seem to have such attention available. As examples, in most chapters references later than 1983 are uncommon except for studies by the author of the chapter. Within a chapter the same material may be discussed in more than one place, to no apparent end. Controversial material is not referenced thoroughly in places. The size of a tumor is given as "1 ml." Such elements add up to less than a confidence-inspiring text. The lack of timeliness in citations in places leaves
Neuroscience, Morality
Authors: Richard Camicioli
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de J. M. Buscaglia et al., pp. 506
Journal: Endoscopy (2008)

See also: Severity of post-ERCP pancreatitis directly proportional to the invasiveness of endoscopic intervention: a pilot study in a canine modelEndoscopy 2008; 40(06): 506-512DOI: 10.1055/s-2007-995653
Leads from the MMWR. HIV-related beliefs, knowledge, and behaviors among high school students
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Electronics
Authors: Lee B. Lusted
Journal: New England Journal of Medicine (1955)

THE large number of medical electronic devices developed in the past year indicates a rapid expansion of this field. Electronic instruments are important medical tools.Electric phenomena in the human body had long been of interest, but the low signal amplitude made study difficult. After De Forest's development of the triode vacuum tube in 1907, electronic equipment was built to amplify the weak electric signals from the heart and central nervous system, and subsequent advances in electronic technics were applied to problems in various medical fields.About 1932 the American Institute of Electrical Engineers gave formal recognition to the problems . . .
Choleriformic Monster
Authors: Henry J. L. Marriott
Journal: New England Journal of Medicine (1956)

WHEN one adds a verbal offspring to an already overpopulated vernacular, one should be very sure what one is doing. As Fowler says, "word-making, like other manufactures, should be done by those who know how to do it; others should neither attempt it for themselves, nor assist the deplorable activities of amateurs by giving currency to fresh coinages before there has been time to test them." One of the latest monsters to rear its ugly bulk is "choleriformic." This has already been born1 and blessed,2 and it is high time for it to be drowned. The word is intended to . . .